close

Agreements

Date: 2015-04-13

Type of information: Milestone

Compound: guselkumab (CNTO1959)

Company: MorphoSys (Germany) Janssen Biotech, a J&J company (USA - NJ)

Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases

Type agreement: R&D - research

Action mechanism: monoclonal antibody. Guselkumab is a human monoclonal antibody that targets interleukin (IL)-23, and is in Phase 3 clinical development as a subcutaneously administered therapy for the treatment of moderate to severe plaque psoriasis.

Disease: psoriatic arthritis

Details:

  • • On April 13, 2015, MorphoSys announced  that Janssen Biotech has initiated a phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
  • MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial). In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 23 unique antibody molecules which are being evaluated in more than 60 clinical trials.

Financial terms:

Latest news:

Is general: Yes